Policy | July 23, 2024
Industry hails Union Budget 2024-25
The Central government’s decision to exempt three more cancer medicines from customs duty is a commendable step towards making cancer drugs more affordable
The Central government’s decision to exempt three more cancer medicines from customs duty is a commendable step towards making cancer drugs more affordable
Phase III ARANOTE trial met primary endpoint, significantly increasing radiological progression-free survival (rPFS) with NUBEQA plus androgen deprivation therapy (ADT) compared to placebo plus ADT
Finance Minister Nirmala Sitharaman is set to present the full budget for the current financial year on July 23
Doxorubicin Hydrochloride Liposome Injection (RLD Doxil) had estimated annual sales of USD 42 million in the U.S. (IQVIA MAT May 2024)
Acquisition to expand Lilly's immunology pipeline with oral integrin therapies
Olverembatinib, a novel drug developed by Ascentage Pharma with support from the National Major New Drug Development program
Utidelone can penetrate BBB due to its unique physicochemical characteristics and insusceptibility to P-glycoprotein-mediated efflux
Acquisition provides Ligand with the royalty rights to QARZIBA, a highly differentiated, commercial oncology drug marketed in 35 countries by global pharmaceutical company Recordati S.p.A.
Partners with Yifan Pharmaceutical to launch Synovian injection for osteoarthritis in China
An investigational CYP11A1 Inhibitor, for the treatment of metastatic castration-resistant prostate cancer
Subscribe To Our Newsletter & Stay Updated
